The present disclosure is directed to a lysin-AMP polypeptide construct comprising: (a) a first component comprising the polypeptide sequence of: (i) SEQ ID NO: 118 (GN202); or (ii) a polypeptide having lysin activity and having at least 80% sequence identity with the polypeptide sequence of SEQ ID NO: 118 (GN202); or (iii) an active fragment of SEQ ID NO: 118 (GN202); and (b) a second component comprising the polypeptide sequence of at least one antimicrobial peptide (AMP), wherein the at least one AMP comprises SEQ ID NO: 114 (FIRL). Exemplary lysin-AMP polypeptides, such as GN370 (SEQ ID NO: 44) as well as methods of treating bacterial infections using the present lysin-AMP polypeptide constructs are also disclosed.

The subject invention provides materials and methods for producing, isolating, extracting and purifying single-molecule products. The subject invention provides materials and methods for extracting microbial metabolites at a high level of purity, for example, a purity of at least 80% by weight, and preferably at least 95% by weight or more. Specifically, the subject invention provides materials and methods for isolating or extracting biosurfactants and polyketides at a high level of purity. Preferably, the biosurfactant is a sophorolipid (SLP).

Disclosed herein are methods for introducing functional mitochondria into liver cells in living animals (e.g., mammals). The disclosed compositions and methods can be used to treat clinical conditions characterized by genetic or acquired mitochondrial defects and the resulting dysfunctions and diseases therefrom.

Disclosed herein are methods for introducing functional mitochondria into liver cells in living animals (e.g., mammals). The disclosed compositions and methods can be used to treat clinical conditions characterized by genetic or acquired mitochondrial defects and the resulting dysfunctions and diseases therefrom.

Some embodiments described herein relate to cells which have been genetically engineered to release a polypeptide when a population of the cells reaches a desired density. In some embodiments, the released polypeptide may be a therapeutic polypeptide. In some embodiments, the therapeutic polypeptide kills tumor cells or which inhibits the growth of tumor cells.

Some embodiments described herein relate to cells which have been genetically engineered to release a polypeptide when a population of the cells reaches a desired density. In some embodiments, the released polypeptide may be a therapeutic polypeptide. In some embodiments, the therapeutic polypeptide kills tumor cells or which inhibits the growth of tumor cells.

The present invention provides a production method for a composition for cell culturing. This production method comprises: (1) a step for subjecting algae to an acid hydrolysis treatment and/or an alkali hydrolysis treatment; (2) a step for neutralizing the hydrolysis product obtained in the step (1) to obtain an algae extract; and (3) a step for mixing the algae extract with a medium for cell culturing, wherein the medium for cell culturing does not substantially contain L-glutamine.

The present invention provides a production method for a composition for cell culturing. This production method comprises: (1) a step for subjecting algae to an acid hydrolysis treatment and/or an alkali hydrolysis treatment; (2) a step for neutralizing the hydrolysis product obtained in the step (1) to obtain an algae extract; and (3) a step for mixing the algae extract with a medium for cell culturing, wherein the medium for cell culturing does not substantially contain L-glutamine.

The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×10.sup.11 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.

The instant technology relates to a production system to produce AAV vectors in a serum free suspension platform and at high titers. This technology uses reagents comprising media, cells, transfection reagent, AAV enhancer, and a lysis buffer, each of which is designed to provide maximal AAV production from suspension culture of mammalian cells, e.g. HEK293 cells. With this new system we are able to deliver up to about 2×10.sup.11 viral genomes per milliliter (vg/mL) of unconcentrated AAV vectors.